Gilead donates over 2,000 vials of remdesivir to support WHO-led Ebola treatment trial
PUBT · 2d ago
Share
Listen to the news
- Gilead will donate more than 2,000 vials of intravenous remdesivir for investigational use in the WHO-led PARTNERS filovirus treatment trial.
- The study targets Bundibugyo virus disease during the ongoing outbreak in the Democratic Republic of the Congo, Uganda.
- Remdesivir is not approved for filovirus disease treatment in any country; safety and efficacy for Ebola and Marburg, including Bundibugyo, remain unestablished.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on July 02, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved